Towards 2022: What are prevention and risk reduction in Alzheimer’s disease?
Hacia 2022: ¿Qué son la prevención y la reducción de riesgos en la enfermedad de Alzheimer?
DOI:
https://doi.org/10.17981/JACN.2.2.2021.00Keywords:
Alzheimer’sDownloads
References
Bateman, R. J.; Xiong, C.; Benzinger, T.; Fagan, A. M.; Goate, A.; Fox, N. C.; Marcus, D. S.; Cairns, N. J.; Xie, X., Blazey, T. M.; Holtzman, D. M.; Santacruz, A.; Buckles, V.; Oliver, A.; Moulder, K.; Aisen, P. S.; Ghetti, B.; Klunk, W. E.; McDade, E.; Martins, R. N.; Masters, C. L.; Mayeux, R.; Ringman, J. M.; Rossor, M. N.; Schofield, P. R.; Sperling, R. A.; Salloway, S. & Morris, J. C. (2012). Clinical and Biomarker Changes in Dominantly Inherited Alzheimer’s disease. The New England Journal of Medicine, 367(9), 795–804.
https://doi.org/10.1056/NEJMoa1202753
Brookmeyer, R.; Johnson, E.; Ziegler-Graham, K. & Arrighi, H. M. (2007). Forecasting the global burden of Alzheimer’s disease. Alzheimer’s & Dementia, 3(3), 186–191.
https://doi.org/10.1016/j.jalz.2007.04.381
Cummings, J.; Lee, G.; Zhong, K.; Fonseca, J. & Taghva, K. (2021). Alzheimer’s disease drug development pipeline: 2021. Alzheimer’s Dement, 7(1), 1–24.
https://doi.org/10.1002/trc2.12179
Feinleib, M. (2001). A Dictionary of Epidemiology, Fourth Edition - Edited by John M. Last, Robert A. Spasoff, and Susan S. Harris. American Journal of Epidemiology, 154(1), 93–94.
https://doi.org/10.1093/aje/154.1.93-a
Getsios, D.; Blume, S.; Ishak, K. J.; Maclaine, G. & Hernández, L. (2012). An economic evaluation of early assessment for Alzheimer’s disease in the United Kigdom. Alzheimer & Dementia, 8(1), 22–30.
https://doi.org/10.1016/j.jalz.2010.07.001
Hodes, J. F.; Oakley, C. L.; O’Keefe, J. H.; Lu, P.; Galvin, J. E.; Saif, N.; Bellara, S.; Rahman, A.; Kaufman, Y.; Hristov, H.; Rajji, T. K.; Fosnacht, A. M.; Patel, S.; Merrill, D. A.; Kaiser, S.; Meléndez-Cabrero, J.; Melendez, J. A.; Krikorian, R. & Isaacson, R. S. (2019). Alzheimer’s “Prevention ”vs.“ Risk Reduction: Transcending Semantics for Clinical Practice. Frontiers in Neurology, 9(1), 1–8.
https://doi.org/10.3389/fneur.2018.01179
Kivipelto, M.; Mangialasche, F.; Snyder, H. M.; Allegri, R. F.; Andrieu, S.; Arai, H.; Baker, L.; Belleville, S.; Brodaty, H.; Brucki, S. M.; Calandri, I.; Caramelli, P.; Chen, C.; Chertkow, H.; Chew, E.; Choi, S. H.; Chowdhary, N.; Crivelli, L.; De La Torre, R.; Du, Y.;Dua, T.; Espeland, M.; Feldman, H. H.; Hartmanis, M.; Hartmann, T.; Heffernan, M.; Henry, C. J.; Hong, C. H.; Håkansson, K.; Iwatsubo, T.; Jeong, J. H.; Jimenez-Maggiora, G.; Koo, E. H.; Launer, L. J.; Lehtisalo, J.; Lopera, F.; Martínez-Lage, P.; Martins, R.; Middleton, L.; Molinuevo, J. L.; Montero-Odasso, M.; Moon, S. Y.; Morales-Pérez, K.; Nitrini, R.; Nygaard, H. B.; Park, Y. K.; Peltonen, M.; Qiu, C.; Quiroz, Y. T.; Raman, R.; Rao, N.; Ravindranath, V.; Rosenberg, A.; Sakurai, T.; Salinas, R. M.; Scheltens, P.; Sevlever, G.; Soininen, H.; Sosa, A. L.; Suemoto, C. K.; Tainta-Cuezva, M.; Velilla, L.; Wang, Y.; Whitmer, R.; Xu, X.; Bain, L. J.; Solomon, A.; Ngandu, T. & Carrillo, M. C. (2020). World-Wide FINGERS Network: A Global Approach to Risk Reduction and Prevention of Dementia. Alzheimers & Dement, 16(1), 1078–1094.
https://doi.org/10.1002/alz.12123
McKhann, G.; Drachman, D.; Folstein, M.; Katzman, R.; Price, D. & Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology, 34(7), 939–944.
https://doi.org/10.1212/wnl.34.7.939
McKhann, G. M.; Knopman, D. S.; Chertkow, H.; Hyman, B. T.; Jack, C. R. Jr, Kawas, C. H, Klunk, W. E; Koroshetz, W. J.; Manly, J. J.; Mayeux, R.; Mohs, R. C.; Morris, J. C.; Rossor, M. N.; Scheltens, P.; Carrillo, M. C.; Thies, B.; Weintraub, S. & Phelps, C. H. (2011). The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging– Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement, 7(3), 263–269.
https://doi.org/10.1016/j.jalz.2011.03.005
Prince, M.; Bryce, R. & Ferri, C. (2011). World Alzheimer Report 2011. The benefits of early diagnosis and intervention. London: ADI. Available:
https://www.alzint.org/resource/world-alzheimer-report-2011/
Sperling, R. A.; Aisen, P. S.; Beckett, L. A.; Bennett, D. A.; Craft, S.; Fagan, A. M.; Iwatsubo, T.; Jack Jr, C. R.; Kaye, J.; Montine, T. J.; Park, D. C.; Reiman, E. M.; Rowe, C. C.; Siemers, E.; Stern, Y.; Yaffe, K.; Carrillo, M. C.; Thies, B.; Morrison-Bogorad, M.; Wagster, M. V. & Phelps, C. H. (2011). Towards defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement, 7, 280–292.
https://doi.org/10.1016/j.jalz.2011.03.003
WHO EMRO. (feb. 1, 2015). Health Promotion and Disease Prevention Through Population-Based Interventions, Including Action to Address Social Determinants and Health Inequity. Genebra: Regional Director/WHO. Available:
http://www.emro.who.int/about-who/public-health-functions/health-promotion-disease-prevention.html
WHO. (2012). Dementia: A Public Health Priority. London: WHO/ADI. Available:
https://apps.who.int/iris/handle/10665/75263
Wimo, A. & Prince, M. (2010). World Alzheimer Report 2010. London: ADI. Available from
https://www.alz.org/documents/national/world_alzheimer_report_2010.pdf
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Journal of Applied Cognitive Neuroscience

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
- NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.